Results 31 to 40 of about 11,363 (187)

Asthma in Children and Adults: A Shared Biological and Molecular Basis

open access: yesCanadian Respiratory Journal, 1995
The objective of this paper is to describe the important clinical, physiological, immunological and biological similarities among asthmatic infants, children and adults. A comparison of the reported clinical presentation, physiological changes, histology
Paolo M Renzi
doaj   +1 more source

Early gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapy. [PDF]

open access: yesPLoS ONE, 2013
Synchrotron Microbeam Radiation Therapy (MRT) relies on the spatial fractionation of the synchrotron photon beam into parallel micro-beams applying several hundred of grays in their paths.
Audrey Bouchet   +9 more
doaj   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

open access: yesPediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean   +7 more
wiley   +1 more source

Opposite effects of interleukin-4 and interleukin-10 on nitric oxide production in murine macrophages

open access: yesMediators of Inflammation, 1996
Interleukin-4 (IL-4) and interleukin-10 (IL-10) were evaluated for their ability to inhibit the production of nitric oxide (NO) by interferon-γ (IFN-γ)- or lipopolysaccharide (LPS)-activated murine macrophages (RAW 264.7 and J774.2).
A. Maru, S. K. Jackson
doaj   +1 more source

Recent advances in immunity to human schistosomiasis

open access: yesMemorias do Instituto Oswaldo Cruz, 1992
For many years the epidemiological significance of immunity in human schistosomiasis has been the subject of inconclusive debate. Recently, the results of studies from Brazil and Kenya, on Shistosoma mansoni and from Zimbabwe and The Gambia on S ...
Paul Hagan, Fredterico G. C. Abath
doaj   +1 more source

Cervical Cytokine Profile in High‐Grade Squamous Intraepithelial Lesions

open access: yesCytopathology, Volume 37, Issue 5, Page 523-530, September 2026.
Hypothetical mechanism of immune modulation in HSIL associated with high‐risk HPV infection, based on observed cytokine suppression. The diagram illustrates impaired Th1 responses, reflected by reduced production of IL‐2 and TNF, which may compromise the activation and cytotoxic function of CD8+ T cells and NK cells, facilitating immune evasion.
Talles Henrique de Araújo Pontes   +8 more
wiley   +1 more source

Immune Response to Conjugates of Fragments of the Type K9 Capsular Polysaccharide of Acinetobacter baumannii with Carrier Proteins

open access: yesMicrobiology Spectrum, 2022
The clonal bacterial species Acinetobacter baumannii is an emerging multidrug-resistant pathogen which causes high-lethality infections. Cells of A. baumannii are surrounded by the type-specific capsular polysaccharide (CPS), which provides resistance to
Natalia Rudenko   +13 more
doaj   +1 more source

Lymphokines in Inflammation

open access: yesAutoimmunity, 1989
An International Symposium organized as the VIth Annual Inflammation Meeting by the Department of Rheumatology, University of Birmingham.
openaire   +2 more sources

Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling

open access: yesFrontiers in Immunology, 2022
Acting on the cytokine cascade is key to preventing disease progression and death in hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 inhibitors have been the most used and studied since the beginning of the pandemic.
Gaetano Zizzo   +7 more
doaj   +1 more source

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

open access: yesCancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy